GB202111288D0 - Combination therapy - Google Patents
Combination therapyInfo
- Publication number
- GB202111288D0 GB202111288D0 GBGB2111288.3A GB202111288A GB202111288D0 GB 202111288 D0 GB202111288 D0 GB 202111288D0 GB 202111288 A GB202111288 A GB 202111288A GB 202111288 D0 GB202111288 D0 GB 202111288D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- combination therapy
- therapy
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2111288.3A GB202111288D0 (en) | 2021-08-04 | 2021-08-04 | Combination therapy |
| PCT/EP2022/071877 WO2023012244A1 (en) | 2021-08-04 | 2022-08-03 | Combination therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2111288.3A GB202111288D0 (en) | 2021-08-04 | 2021-08-04 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202111288D0 true GB202111288D0 (en) | 2021-09-15 |
Family
ID=77651280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2111288.3A Ceased GB202111288D0 (en) | 2021-08-04 | 2021-08-04 | Combination therapy |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB202111288D0 (en) |
| WO (1) | WO2023012244A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270657B (en) * | 2023-05-18 | 2023-08-18 | 智泽童康(广州)生物科技有限公司 | Pharmaceutical composition for preventing and/or treating gastrointestinal diseases and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920008160B1 (en) * | 1990-06-01 | 1992-09-24 | 윤택구 | Pharmaceutical composition for cancer prevention |
| KR101424833B1 (en) * | 2006-06-27 | 2014-08-01 | 코와 가부시키가이샤 | Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue |
| TW200824676A (en) * | 2006-10-24 | 2008-06-16 | Kowa Co | Cardiovascular drug |
| ES2965201T3 (en) * | 2016-02-29 | 2024-04-11 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Use of bile acids and bile salts as antibacterial agents for the inhibition of bacterial conjugation and horizontal gene transfer |
| KR102093872B1 (en) * | 2017-07-03 | 2020-03-27 | 진호성 | Injection Composition For Fat Reduction and method of manufacturing the same |
| US20200397807A1 (en) * | 2019-06-18 | 2020-12-24 | MitoPower, LLC | Nicotinyl riboside compounds and their uses |
-
2021
- 2021-08-04 GB GBGB2111288.3A patent/GB202111288D0/en not_active Ceased
-
2022
- 2022-08-03 WO PCT/EP2022/071877 patent/WO2023012244A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023012244A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304223A (en) | Combination therapy | |
| IL319599A (en) | Combination therapy | |
| GB202103164D0 (en) | Therapy | |
| GB202004189D0 (en) | Combination therapy | |
| GB202002639D0 (en) | Therapy | |
| IL318268A (en) | Combination therapy | |
| GB202111288D0 (en) | Combination therapy | |
| GB202104037D0 (en) | Combination therapy | |
| GB202111035D0 (en) | Therapy | |
| GB202108303D0 (en) | Therapy | |
| GB202109375D0 (en) | Combination therapy | |
| GB202109377D0 (en) | Combination therapy | |
| GB202109373D0 (en) | Combination therapy | |
| GB202107824D0 (en) | Combination therapy | |
| GB202107713D0 (en) | Combination therapy | |
| GB202107709D0 (en) | Combination therapy | |
| GB202107706D0 (en) | Combination therapy | |
| GB202015916D0 (en) | Combination therapy | |
| GB202012161D0 (en) | Combination therapy | |
| GB202009178D0 (en) | Combination therapy | |
| GB202117706D0 (en) | Therapy | |
| GB202109893D0 (en) | PeptiBAC therapy | |
| GB202104427D0 (en) | Therapy | |
| GB202102211D0 (en) | PeptiBAC therapy | |
| GB202019218D0 (en) | Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |